FDA Rejects Allergan’s Levadex Due to CMO Concerns

Drug GMP Report
A A
Allergan has received a complete response letter (CRL) for its aerosol-based migraine drug Levadex.

To View This Article:

Login

Subscribe To Drug GMP Report

Buy This Article Now

Add this article to your cart for $40.00